Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00879177 · ClinicalTrials.gov registry record · Phase 4
Smoking Study With Behavioral Therapy for Hypertensive Patients
A Phase 4 study of Hypertension and Cigarette Smoking, sponsored by UConn Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 203
- Enrollment target
- 1
- Study location
NCT00879177 is a Phase 4 study of Hypertension and Cigarette Smoking that has completed, run by UConn Health. The registered enrollment target is 203 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00879177, a Phase 4 study of Hypertension and Cigarette Smoking, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 203 participants
- Enrollment target
- 1
- Study location
Study Summary
In total, 260 patients with pre- and stage I hypertension, who are regular smokers, will be randomized to: varenicline alone or varenicline plus behavioral therapy. Patients in both conditions will receive varenicline (titrated to a maximal dose of 1.0 mg twice daily) for 12 weeks along with standard smoking cessation therapy and regular carbon monoxide (CO) and cotinine monitoring. A significantly higher proportion of behavioral therapy patients are expected to achieve and maintain long durations of abstinence than patients receiving varenicline alone. Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be primary clinical outcomes. The investigators expect that BP and HR will decrease more among behavioral therapy than non-behavioral therapy patients and reductions in smoking may mediate decreases in these indices.
Conditions Studied
Interventions
- DRUG Varenicline
- BEHAVIORAL behavioral therapy
Study Locations (1)
Connecticut
- University of Connecticut Health Center - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2009-04 |
| Est. Completion | 2014-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00879177
The ClinicalTrials.gov registry entry for NCT00879177 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 203 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (94% lower). The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Varenicline is the first listed.
NCT00879177 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00879177 about?
NCT00879177 is a clinical study titled "Smoking Study With Behavioral Therapy for Hypertensive Patients". In total, 260 patients with pre- and stage I hypertension, who are regular smokers, will be randomized to: varenicline alone or varenicline plus behavioral therapy. Patients in both conditions will receive varenicline (titrated to a maximal dose of 1.0 mg twice daily) for 12 weeks along with standar...
What is the current status of trial NCT00879177?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 203 participants. The study started on 2009-04. Estimated completion is 2014-11.
What conditions does trial NCT00879177 study?
This clinical trial studies the following conditions: Hypertension, Cigarette Smoking.
What interventions are being tested in trial NCT00879177?
The interventions under investigation include: Varenicline (DRUG), behavioral therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00879177?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00879177 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.